The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Domain registration === In 2005, Nominet determined the domain name bocedwards.co.uk had been abusively registered by Eaton Engineering (Herts) Ltd and ordered that it be transferred to The BOC Group Ltd, the then owners of Edwards.
=== Allenstein / Olsztyn Plebiscite Area === The Allied forces had to intervene here in 1919 to release imprisoned Masurians, who had tried to reach the Paris Conference. The president and British commissioner of the Inter-Allied Administrative and Plebiscite Commission for Allenstein was Ernest Rennie; the French commissioner was Couget; the Italian commissioner was Marquis Fracassi, a senator; and the Japanese commissioner was Marumo. The German government, under the Protocol's terms, was allowed to attach a delegate and sent Reichskommissar Wilhelm von Gayl, who had been in the service of the Interior Ministry before he was on the Inner Colonisation Committee. The local police forces were placed under the control of two British officers: Lieutenant-Colonel Bennet and Major David Deevis. Bennet reported that he regarded them as "well-disciplined and reliable". There was also a battalion from the Royal Irish Regiment and an Italian regiment stationed at Lyck (Ełk).
reading frame A way of dividing the nucleotide sequence in a DNA or RNA molecule into a series of consecutive, non-overlapping groups of three nucleotides, known as triplets, which is how the sequence is interpreted or "read" by ribosomes during translation. In coding DNA, each triplet is referred to as a codon and corresponds to a particular amino acid to be added to the nascent peptide chain during translation. In general, only one reading frame (the so-called open reading frame) in a given sequence encodes a functional protein, though there are exceptions. A frameshift mutation results in a shift in the normal reading frame which affects all downstream codons and usually results in a completely different and senseless amino acid sequence.
Sources: en.wikipedia.org
Owing to its location, the present territory of Colombia was a corridor of early human civilization from Mesoamerica and the Caribbean to the Andes and Amazon basin. The oldest archaeological finds are from the Pubenza and El Totumo sites in the Magdalena Valley 100 kilometers (62 mi) southwest of Bogotá. These sites date from the Paleoindian period (18,000–8000 BCE). At Puerto Hormiga and other sites, traces from the Archaic Period (~8000–2000 BCE) have been found. Vestiges indicate that there was also early occupation in the regions of El Abra and Tequendama in Cundinamarca. The oldest pottery discovered in the Americas, found in San Jacinto, dates to 5000–4000 BCE. Indigenous people inhabited the territory that is now Colombia by 12,500 BCE. Nomadic hunter-gatherer tribes at the El Abra, Tibitó and Tequendama sites near present-day Bogotá traded with one another and with other cultures from the Magdalena River Valley. A site including eight miles (13 km) of pictographs that is under study at Serranía de la Lindosa was revealed in November 2020. Their age is suggested as being 12,500 years old (c. 10,480 B.C.) by the anthropologists working on the site, because of extinct fauna depicted. It was during the earliest known human occupation of the area. Between 5000 and 1000 BCE, hunter-gatherer tribes transitioned to agrarian societies; fixed settlements were established, and pottery appeared.
Raicho Kimikage (君影 雷鳥, Kimikage Raichō) Agent of Summer's Guard Candidate, Ruri's fiancé. He's a confident, sometimes arrogant man. Most people consider him weird, but he's kind and devoted to those he respects. He's madly in love with Ruri. Renri Rouo (老鶯 連理, Rōō Renri) Town of Summer doctor and Ayame's fiancé. He is a doctor affiliated with the town's medical practice. Despite his playboy appearance, he is kind and gentle. He wishes to marry Ayame, but there is a big secret between them.
Macallum, A.B. & Collop (sic), J.B. (1914), "A New Substance in Nerve Cells" (read: Monday, 15 September 1913), Report of the Eighty-Third Meeting of the British Association for the Advancement of Science: Birmingham: 1913: September 10-17 (Physiology Section), pp. 673–674. Marier, Virginie & Piper, Tina (2010), "Early Twentieth-Century Canadian Medical Patent Law in Practice: James Bertram Collip and the Discovery of Emenin", University of Toronto Law Journal, Vol.60, No.3, (Summer 2010), pp. 855-892. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it".
A/B testing (also known as bucket testing, split-run testing or split testing) is a user-experience research method. A/B tests consist of a randomized experiment that usually involves two variants (A and B), although the concept can be also extended to multiple variants of the same variable. It includes application of statistical hypothesis testing or "two-sample hypothesis testing" as used in the field of statistics. A/B testing is employed to compare multiple versions of a single variable, for example by testing a subject's response to variant A against variant B, and to determine which of the variants is more effective. Multivariate testing or multinomial testing is similar to A/B testing but may test more than two versions at the same time or use more controls. Simple A/B tests are not valid for observational, quasi-experimental or other non-experimental situations—commonplace with survey data, offline data, and other, more complex phenomena.
Sources: en.wikipedia.org
20983Bi + 6428Ni → 272111 + 10n This reaction had previously been conducted at the Joint Institute for Nuclear Research in Dubna (then in the Soviet Union) in 1986, but no atoms of 272111 had then been observed. In 2001, the IUPAC/IUPAP Joint Working Party (JWP) concluded that there was insufficient evidence for the discovery at that time. The GSI team repeated their experiment in 2002 and detected three more atoms. In their 2003 report, the JWP decided that the GSI team should be acknowledged for the discovery of this element.
Promising results of health and medical research are reported: non-human vaccinated primates-tested pGal–antigen therapy for suppressing antigen-specific immune responses and against autoimmune diseases, this type of vaccine is called "inverse vaccine" (7 Sep), 3D cell-culture tested exercise-induced hormone irisin against Aβ Alzheimer's disease pathology (8 Sep), identified diverse features strongly associated with long COVID for better diagnosis (25 Sep). Promising innovations relating to global challenges are reported: a study winning an international competition demonstrates an approach that predicted 70% of earthquakes, suggesting some form of earthquake prediction may be feasible in the future (5 Sep), researchers release a large set of audiobooks for books in Project Gutenberg created automatically via generative AI with near-natural voice (7 Sep), a news outlet reports on a natural language system, demonstrated on 27 July, that can provide explanations for the conclusion-making of machine learning models for explainable AI (12 Sep), researchers report a production method for spider silk fibers from gene-edited transgenic silkworms for a sustainable alternative material six times stronger than Kevlar (20 Sep), a new generation of sleeping trains is presented amid a comeback of this transport technology in Europe as demand for more comfortable travel modes than overnight buses and sustainable transport rises (30 Sep).
===== Laurasiatheria ===== Order Artiodactyla (even-toed ungulates) Family Antilocapridae Antilocapra americana, pronghorn (2019) Family Balaenidae Balaena mysticetus, bowhead whale (2015) Eubalaena glacialis, North Atlantic right whale (2018) Family Balaenopteridae Balaenoptera acutorostrata, common minke whale (2014) Balaenoptera borealis, sei whale (2018) Balaenoptera musculus, blue whale (2018) Balaenoptera physalus, fin whale (2014) Megaptera novaeangliae, humpback whale (2018) Family Bovidae Ammotragus lervia, Barbary sheep (2019) Antidorcas marsupialis, Springbox (2019) Bison bonasus, European bison (2017) Bos grunniens, yak 2012 () Bos primigenius indicus, zebu or Brahman cattle (2012) Bos primigenius taurus, cow 2009 () Bubalus bubalis, river buffalo (2017) Budorcas taxicolor, Takin (2023) Capra ibex, Goats (2019) Cephalophus harveyi, Harvey's duiker (2019) Connochaetes taurinus, blue wildebeest (2019) Damaliscus lunatus, common tsessebe (2019) Gazella thomsoni, Thomson's gazelle (2019) Hippotragus niger, Sable Antelope (2019) Kobus ellipsiprymnus, Waterbuck (2019) Litocranius walleri, Gerenuk (2019) Oreotragus oreotragus, Klipspringer (2019) Oryx gazella, Gemsbok (2019) Ourebia ourebi, Oribi (2019) Ovis ammon, Argali (2019) Ovis ammon polii, marco polo sheep (2017) Nanger granti, Grant's gazelle (2019) Neotragus moschatus, Suni (2019) Neotragus pygmaeus, Royal antelope (2019) Philantomba maxwellii, Maxwell's duiker (2019) Procapra przewalskii, Przewalski's gazelle (2019) Pseudois nayaur, Bharal (2019) Pseudoryx nghetinhensis, Saola (2025) Raphicerus campestris, Steenbox (2019) Redunca redunca, Bohor reedbuck (2019) Syncerus caffer, African buffalo (2019) Sylvicapra grimmia, common duiker (2019) Tragelaphus, Spiral-horned bovine (2019) Tragelaphus buxtoni, Mountain nyala (2019) Tragelaphus strepsiceros, Greater kudu (2019) Tragelaphus imberbis, Lesser kudu (2019) Tragelaphus spekii, Sitatunga (2019) Tragelaphus scriptus, Bushbuck (2019) Taurotragus oryx, Common eland (2019) Family Camelidae Camelus ferus, Wild Bactrian camel (2007) Family Cervidae Cervus albirostris, Tharold's deer (2019) Elaphurus davidianus, Père David's deer (2018) Muntiacus crinifrons, hairy-fronted muntjac (2019) Muntiacus muntjak, Indian muntjac (2019) Muntiacus reevesi, Reeves's muntjac (2019) Odocoileus hemionus, mule deer (2021) Rangifer tarandus, Reindeer (2017) Rusa alfredi, Visayan spotted deer (2025) Family Delphinidae Tursiops truncatus, bottlenosed dolphin (2012) Neophocaena phocaenoides, finless porpoise (2014) Orcinus orca, killer whale (2015) Sousa chinensis, Indo-Pacific humpback dolphin (2019) Family Eschrichtiidae Eschrichtius robustus, gray whale (2018) Family Giraffidae Giraffa camelopardalis, Giraffe (2019) Giraffa camelopardalis tippelskirchi, Masai giraffe (2019) Okapia johnstoni, Okapi (2019) Family Monodontidae Delphinapterus, beluga whale (2017) Family Moschidae Moschus berezovskii, forest musk deer (2018) Moschus chrysogaster, Alpine musk deer (2019) Family Phocoenidae Neophocaena asiaeorientalis sunameri, East Asian finless porpoise (2024) Neophocaena asiaorientalis asiaorientalis, Yangtze finless porpoise (2024) Family Physeteridae Physeter macrocephalus, sperm whale (2019) Family Suidae Sus scrofa, pig (2012) Family Tragulidae Tragulus javanicus, Java mouse-deer (2019) Order Carnivora Family Felidae Acinonyx jubatus, cheetah (2015) Felis catus, cat (2007) Panthera leo, lion (2013) Panthera pardus, Amur leopard (2016) Panthera tigris tigris, Siberian tiger (2013) Panthera tigris tigris, Bengal tiger (2013) Panthera uncia, snow leopard (2013) Prionailurus bengalensis, leopard cat (2016) Family Canidae Canis familiaris, dog (2005) Canis lupus lupus, wolf (2017). Lycaon pictus, african wild dog (2018) Family Ursidae Ailuropoda melanoleuca, giant panda (2010) Ursus arctos ssp. horribilis, Grizzly bear (2018) Ursus americanus, American black bear (2019) Ursus maritimus, Polar bear (2014) Family Odobenidae Odobenus rosmarus, walrus (2015) Family Phocidae Pusa sibirica, Baikal seal (2024) Pusa caspica, Caspian seal (2024) Phoca vitulina, Harbor seal (2024) Pusa hispida, Ringed seal (2024) Family Mustelidae Enhydra lutris kenyoni, sea otter (2017) Mustela erminea, stoat (2018) Mustela furo, ferret (2014) Pteronura brasiliensis, giant otter (2019) Order Chiroptera Family Megadermatidae Megaderma lyra, greater false vampire bat (2013) Family Mormoopidae Pteronotus parnellii, Parnell's mustached bat (2013) Family Pteropodidae Pteropus vampyrus, fruit bat (2012) Eidolon helvum, Old World fruit bat (2013) Family Rhinolophidae Rhinolophus ferrumequinum, greater horseshoe bat (2013) Family Vespertilionidae Myotis lucifugus, little brown bat (2010) Myotis mystacinus, whiskered bat (2024) Family Phyllostomidae Leptonycteris yerbabuenae, long nosed bat (2020) Leptonycteris nivalis, greater long nosed bat (2020) Musonycteris harrisoni, banana bat (2020) Artibeus jamaicensis, Jamaican fruit bat (2020) Macrotus waterhousii, Waterhouse's leaf-nosed bat (2020 Order Erinaceomorpha, Family Erinaceidae Erinaceus europaeus, western European hedgehog () Order Eulipotyphla, Family Solenodontidae Solenodon parodoxus, Hispaniolan solenodon (2018) Order Perissodactyla (odd-toed ungulates) Family Equidae Equus caballus, horse (2009 2018)
==== Wound healing ==== Nanogels are a promising technology being explored to aid in the wound healing process. Given their ability to encapsulate various types of cargo, nanogels can strategically deliver anti-inflammatory agents, antimicrobial drugs, and necessary growth factors to facilitate new tissue growth and blood vessel formation. Chitosan-based nanogels have demonstrated an improved wound healing effect in previous studies. Chitosan-based nanogels encapsulating interleukin-2 were successfully used to stimulate the immune system and advance the wound healing process. Additionally, chitosan-based nanogels carrying an antibiotic, silver sulfadiazine, were found to decrease the size of second-degree burns in one in vivo study. In another study, silver-loaded nanogels were synthesized in a natural polymer-based solution containing aloe vera, and the presence of aloe vera led to increased healing and a decrease in wound size. With the goal of preventing infection and accelerating the healing process, one group has also published a new nanogel design consisting of an encapsulating core and a functionalized outer surface capable of targeting bacteria present in wounds.
3D food printing is the process of manufacturing food products using a variety of additive manufacturing techniques. Most commonly, food grade syringes hold the printing material, which is then deposited through a food grade nozzle layer by layer. The most advanced 3D food printers have pre-loaded recipes on board and also allow the user to remotely design their food on their computers, phones or some IoT device. The food can be customized in shape, color, texture, flavor or nutrition, which makes it very useful in various fields such as space exploration and healthcare.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.